SCHEMBL24711986

SCHEMBL24711986

Cc1c(Br)ccc2c(N3CCCOCC3)nc(Cl)nc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.44
ALDH1A1 P00352 5/20 0.40
KDM4E B2RXH2 4/20 0.40
MAPK1 P28482 4/20 0.40
GBA1 P04062 1/20 0.39
MAPT P10636 1/20 0.39
TSHR P16473 2/20 0.39
ALOX15 P16050 2/20 0.38
LMNA P02545 2/20 0.38
USP2 O75604 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
CASP7 P55210 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
PRKDC P78527 1/20 0.37
HPGD P15428 2/20 0.37
GLA P06280 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24712657 0.86 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1KDM4EMAPK1GBA1
SCHEMBL24712352 0.80 CYP1A2 (0.37) SMN1; SMN2ALDH1A1KDM4EMAPK1MAPT
SCHEMBL2726482 0.80 HRH4 (0.50) SMN1; SMN2ALDH1A1KDM4EMAPK1MAPT
SCHEMBL24712889 0.80 PTGS2 (0.39)
SCHEMBL24712656 0.78 PTGS2 (0.35) SMN1; SMN2ALDH1A1KDM4EALOX15HPGD
SCHEMBL24711975 0.75 PRKCH (0.35) SMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL9404476 0.74 KDM4E (0.50) SMN1; SMN2ALDH1A1KDM4EMAPK1MAPT
SCHEMBL25081570 0.73 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1KDM4EMAPK1GBA1
SCHEMBL16166887 0.73 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1KDM4EMAPK1MAPT
SCHEMBL30742492 0.72 ALDH1A1 (0.51) ALDH1A1KDM4EMAPK1GBA1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240287078-A1 QUINAZOLINE DERIVATIVES USEFUL AS RAS INHIBITORS REDX PHARMA PLC (GB) 2024-08-29 US disclosed
EP-4352061-A1 QUINAZOLINE DERIVATIVES USEFUL AS RAS INHIBITIORS Redx Pharma Plc (GB) 2024-04-17 EP disclosed
CN-117425658-A Quinazoline derivatives as RAS inhibitors 莱德克斯制药公共有限公司 2024-01-19 CN disclosed
WO-2022258974-A1 QUINAZOLINE DERIVATIVES USEFUL AS RAS INHIBITIORS REDX PHARMA PLC (GB) 2022-12-15 WO disclosed
WO-2022258974-A1 QUINAZOLINE DERIVATIVES USEFUL AS RAS INHIBITIORS REDX PHARMA PLC (GB) 2022-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287078-A1 QUINAZOLINE DERIVATIVES USEFUL AS RAS INHIBITORS KRAS, NRAS, HRAS SMN1; SMN2 4726/4885ALDH1A1 3891/4885KDM4E 3121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.